Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05216991 · ClinicalTrials.gov registry record
Sugammadex and Quantitative Monitoring in "Fast-Track Anesthesia" During Liver Transplantation
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 97
- Enrollment target
NCT05216991: Completed study, sponsored by Mayo Clinic.
NCT05216991 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 97 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05216991 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 97 participants
- Enrollment target
Study Summary
The purpose of this research is to estimate the frequency of postoperative lasting muscle weakness in patients receiving Sugammadex after undergoing liver transplant surgery by using electromyographic device (EMG), such as TetraGraph.
Interventions
- OTHER TetraGraph on dominant hand
- OTHER TetraGraph on non-dominant hand
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2022-10-20 |
| Est. Completion | 2025-01-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05216991
The ClinicalTrials.gov registry entry for NCT05216991 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TetraGraph on dominant hand is the first listed.
NCT05216991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05216991 about?
NCT05216991 is a clinical study titled "Sugammadex and Quantitative Monitoring in "Fast-Track Anesthesia" During Liver Transplantation". The purpose of this research is to estimate the frequency of postoperative lasting muscle weakness in patients receiving Sugammadex after undergoing liver transplant surgery by using electromyographic device (EMG), such as TetraGraph.
What is the current status of trial NCT05216991?
This trial is currently completed. The enrollment target is 97 participants. The study started on 2022-10-20. Estimated completion is 2025-01-21.
What interventions are being tested in trial NCT05216991?
The interventions under investigation include: TetraGraph on dominant hand (OTHER), TetraGraph on non-dominant hand (OTHER).
Who is sponsoring clinical trial NCT05216991?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.